See the DrugPatentWatch profile for tazverik
What does “tazverik peak sales” mean for Epizyme?
“Tazverik” is tazemetostat (Epizyme’s EZH2 inhibitor). A “peak sales estimate” is an analyst-style forecast of the highest annual revenue a drug could reach at maturity, after ramp-up from launch and market adoption. Specific peak-sales numbers depend on assumptions about treated patient counts, uptake, pricing, line of therapy, geography, and whether the label expands beyond the initial indications.
What peak sales estimates are available for tazemetostat (Tazverik)?
The provided information does not include any published or consensus “peak sales” figures for tazemetostat from analyst reports, company guidance, or market research. Without those sources, a concrete peak sales estimate (a dollar range and year) can’t be stated accurately.
Why estimates for Tazverik peak sales vary by source
Even when a peak-sales number exists, different forecasts can differ substantially because of:
- Assumed addressable populations for each indication (and whether later expansions are included).
- Adoption speed (how quickly clinicians move patients to tazemetostat within a treatment sequence).
- Competition from other EZH2-targeting approaches and standard-of-care therapies.
- Pricing and reimbursement dynamics by country/insurer.
- Duration of use and response rates (which affect switching and long-term treatment patterns).
How to get the most accurate peak-sales estimate for your use case
If you’re trying to estimate peak sales for investment or research, the most reliable path is to use a named consensus or report that states:
- The forecast horizon (for example, peak year).
- The peak annual sales value (often by indication and region).
- Key drivers and base-case assumptions.
- Whether forecasts are updated after label changes, trial readouts, or payer decisions.
If you share the indication(s) you care about (for example, relapsed/refractory follicular lymphoma vs other listed uses) and the region (US only vs global), I can help you frame exactly what to look for in the estimate and how to interpret it.
Quick clarification to pinpoint the right number
What peak sales number are you looking for?
1) US peak sales or global peak sales, and
2) for which indication(s) of tazemetostat?
Answer those two, and I’ll align the estimate to the correct market definition.